|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer
DOI: 10.1038/s41523-018-0060-z
Aditya Bardia, Beth Overmoyer, Carlos R. Gil Del Alcazar, Daniel G. Stover, Eric P. Winer, Franziska Michor, Hao Guo, Jane Brock, Justin Balko, Kornelia Polyak, Maxwell Lloyd, Nancy U. Lin, Qiong Xu, Rebecca Gelman, Sara M. Tolaney, Vivian Wang, Yaomin Xu, Yu Wang
Abstract:
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
